PLK1 PROTAC Compound Selective Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional PLK1 inhibitors fail to sufficiently inhibit PLK1 activity at clinically safe concentrations, and PROTAC compounds targeting both PLK1 and BRD4 often result in excessive BRD4 inhibition leading to toxic side effects.
Innovation Solution
Development of a novel PROTAC compound that selectively degrades PLK1 while degrading BRD4 to an appropriate level, minimizing side effects by using a bifunctional compound with a target protein binding moiety and an E3 ubiquitin ligase binding moiety linked by a chemical linker.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PLK1 inhibitors are used to inhibit PLK1 activity, then PLK1 activity is suppressed, but the inhibition is insufficient at clinically safe concentrations
Solution Approach 1:
The patent replaces the conventional mechanism of PLK1 inhibition (small molecule binding to active site) with a proteolysis-based mechanism (PROTAC-induced degradation). Instead of merely blocking the enzyme active site, the bifunctional compound recruits E3 ubiquitin ligase to ubiquitinate and degrade PLK1 protein, providing more reliable and sustained inhibition at clinically safe concentrations.
Solution Approach 2:
The patent changes the mode of action from reversible enzyme inhibition to irreversible protein degradation. This fundamental parameter change in the inhibition mechanism transforms transient cell cycle delay into sustained PLK1 depletion, achieving reliable clinical effects without requiring high concentrations that would cause toxicity.
2Adaptability or versatility
If PROTAC compounds are designed to simultaneously degrade both PLK1 and BRD4, then dual target degradation is achieved, but excessive BRD4 inhibition causes toxic side effects
Solution Approach 1:
The patent applies local quality by creating asymmetric degradation profiles for the two target proteins. The compound is designed to preferentially degrade PLK1 while maintaining BRD4 at appropriate levels, rather than uniformly degrading both targets. This localized control of degradation intensity at each target site eliminates toxic side effects while preserving therapeutic efficacy.
Solution Approach 2:
The patent implements partial action by intentionally allowing BRD4 to remain partially present rather than completely degrading it. This controlled partial degradation of BRD4 prevents the toxic side effects associated with excessive BRD4 inhibition, while still achieving sufficient PLK1 degradation for cancer treatment. The compound achieves the desired effect by degrading PLK1 to the extent needed without over-degrading BRD4.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively targets and degrades PLK1 with strong inhibition while degrading BRD4 at a level that reduces the risk of side effects, making it suitable for cancer and neurological disease treatment.
Implementation Method 1
proteolysis targeting chimera (PROTAC) has recently been proposed as a small molecule-based platform technology capable of inducing proteolysis of target proteins in the body
Implementation Method 2
an E3 ubiquitin ligase binding moiety are linked by a chemical linker. The PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase
Data Source
AI summary
The present invention relates to a PLK1 protein degradation inducing compound, a preparation method thereof, and a use thereof. Compounds of the present invention target PLK1 and BRD4 to degrade PLK1, and decompose BRD4 to a suitable level within the scope of causing no side effects, and thus can be very advantageously used for prevention or treatment of cancer or neural disease.